AG真人官方

IonQ, Inc. (IONQ) 鈥� Form 4 insider transaction dated 07 July 2025

Director Kathryn K. Chou exercised 5,000 stock options at an exercise price of $4.61 (Code M) and immediately sold the same 5,000 common shares on the open market at $46.18 (Code S) under a pre-arranged Rule 10b5-1 trading plan adopted 12 March 2025.

Following the transactions she directly owns 67,628 shares of IonQ common stock. Her remaining unexercised option position totals 44,900 shares from an original 63,900-share grant that vests in three equal annual instalments through 11 July 2025 and expires 11 July 2032.

The sale represents approximately 7.4 % of her direct equity stake, signalling partial profit-taking while retaining a majority holding.

IonQ, Inc. (IONQ) 鈥� Form 4 insider transaction dated 07 July 2025

Director Kathryn K. Chou exercised 5,000 stock options at an exercise price of $4.61 (Code M) and immediately sold the same 5,000 common shares on the open market at $46.18 (Code S) under a pre-arranged Rule 10b5-1 trading plan adopted 12 March 2025.

Following the transactions she directly owns 67,628 shares of IonQ common stock. Her remaining unexercised option position totals 44,900 shares from an original 63,900-share grant that vests in three equal annual instalments through 11 July 2025 and expires 11 July 2032.

The sale represents approximately 7.4 % of her direct equity stake, signalling partial profit-taking while retaining a majority holding.

Accenture plc (ACN) 鈥� Form 4 insider transaction

General Counsel and Corporate Secretary Joel Unruch reported the purchase of 90 Class A ordinary shares on 05 July 2025 at an average price of $303.795 per share. The acquisition was made through the company鈥檚 Voluntary Equity Investment Program, a payroll-deduction plan that allows executives to buy stock directly from Accenture. Following the transaction, Unruch鈥檚 direct holdings increased to 17,541 shares.

No derivative securities were involved and no dispositions were reported. The filing reflects an incremental ownership increase of roughly 0.5% to Unruch鈥檚 personal stake and is immaterial relative to Accenture鈥檚 total shares outstanding. Because the shares were purchased under a pre-arranged company program rather than on the open market, the signal is less indicative of discretionary conviction, but it nevertheless aligns executive interests with shareholders.

IonQ (NYSE: IONQ) has launched a $1.0 billion capital raise through a mixed offering of 14.17 million new common shares at $55.49 and 39.9 million warrants (36.0 million Series A at a $99.88 strike and 3.86 million pre-funded warrants at $0.0001). The gross proceeds total $1.0 billion and net proceeds, after $20.0 million in underwriting fees and $1.5 million in expenses, are projected at $978.5 million.

The financing will lift total shares outstanding from 243.1 million to 283.9 million immediately (323.8 million if all warrants are exercised), representing dilution of ~17% (or ~33%). Purchasers will experience an immediate $48.96 per-share dilution to adjusted tangible book value ($6.53 post-deal versus the $55.49 offer price). The offering price stands roughly 25% above the $44.39 closing price on 3 July 2025, signaling strong institutional demand despite dilution.

Use of proceeds: working capital, R&D, and potential strategic acquisitions/partnerships that could accelerate IonQ鈥檚 roadmap toward higher-fidelity, larger-qubit quantum systems. J.P. Morgan acts as sole underwriter; warrants will not be exchange-listed, limiting near-term liquidity.

Key risks disclosed include ongoing operating losses (accumulated deficit $716.0 million), execution challenges in scaling quantum hardware, absence of cash dividends, limited warrant liquidity, and only a 60-day lock-up on insider sales.

IonQ, Inc. (NYSE: IONQ) has launched a sizeable capital raise via a Rule 424(b)(5) prospectus supplement dated 7 July 2025. The company is offering (i) 14,165,708 new common shares at $55.49 each, (ii) 36,042,530 seven-year Series A warrants with a cash exercise price of $99.88 per share, and (iii) 3,855,557 seven-year pre-funded warrants with a de-minimis $0.0001 exercise price. The supplement also covers 39,898,087 shares issuable upon warrant exercise.

The sole book-runner is J.P. Morgan. Gross proceeds from the equity component are expected to be 鈮�$1.0 billion; after underwriting discounts of $19.999 million (1.999%) and estimated expenses of $1.5 million, net proceeds should total 鈮�$978.5 million (excluding any future warrant exercises). The Series A warrants are offered at no additional consideration; underwriting fees apply only to the shares and pre-funded warrants.

Capitalisation & dilution

• Shares outstanding will rise from 243,068,917 to 283,881,920; full warrant exercise would lift the count to 323,780,007.
• Net tangible book value per share increases from $2.99 to $6.53; investors buying at $55.49 face an immediate $48.96 per-share dilution.

Use of proceeds is broadly defined: working capital, general corporate purposes and potential strategic acquisitions or partnerships. Until deployed, funds may be invested in short- and intermediate-term U.S. government or investment-grade instruments.

Key structural features

• No exchange listing is planned for either warrant series, limiting liquidity.
• Each holder鈥檚 warrant exercises are capped at 4.99% beneficial ownership.
• Series A warrants may become cash-settled at 鈥淏lack-Scholes value鈥� upon certain fundamental transactions.
• The company and insiders are subject to a 60-day lock-up (with customary carve-outs).

Risk disclosure highlights include (1) management鈥檚 broad discretion over proceeds, (2) substantial dilution to new investors, (3) volatility of IONQ shares which may impair warrant value, and (4) absence of a public market for the warrants.

The last reported share price on 3 July 2025 was $44.39, a 20% discount to the offer price, implying the raise is priced at a premium to market. IonQ鈥檚 accumulated deficit as of 31 March 2025 stood at $716 million; the company anticipates continued operating losses as it scales its trapped-ion quantum-computing platform.

IonQ Executive Chair Peter Chapman reported significant insider transactions on June 20, 2025, executed through a pre-planned Rule 10b5-1 trading plan established on March 14, 2025.

Key transaction details:

• Exercised 1,497,311 employee stock options at $0.1334 per share
• Subsequently sold the same number of shares at a weighted average price of $39.931 (range: $39.50-$41.40)
• Post-transaction holdings: 390,329 shares held directly and 107,661 remaining stock options

The transactions were executed under a Rule 10b5-1 plan, which provides a safe harbor from insider trading allegations by establishing predetermined trading parameters. Chapman's remaining stock options are fully vested and exercisable, with an expiration date of May 16, 2029.

IonQ, Inc. (IONQ) has filed a Form 144 indicating an additional insider share sale. Peter Chapman intends to sell 1,497,311 shares of common stock through Merrill Lynch on or about 20 June 2025 on the NYSE. Based on the filing, IonQ has 261.6 million shares outstanding, so the proposed sale represents roughly 0.6 % of shares outstanding.

The filing also discloses that Chapman has already disposed of 4,491,933 shares in the past three months in two separate transactions dated 16 and 17 June 2025, generating US$171 million in gross proceeds. Taken together, recent and proposed sales total about 5.99 million shares, or ~2.3 % of outstanding stock.

All shares derive from stock-option exercises originally acquired on 17 Nov 2019. No material adverse, non-public information is acknowledged by the filer, and the sale may be conducted under a Rule 10b5-1 trading plan (date not provided). Apart from the sale notice, the document contains no operating metrics, earnings data, or strategic commentary.

Key datapoints

• Shares to be sold: 1,497,311
• Aggregate market value of proposed sale: US$59.7 million
• Broker: Merrill Lynch, San Francisco
• Issuer shares outstanding: 261.6 million
• Prior 3-month insider sales: 4.49 million shares for US$171 million

The elevated volume of insider selling, especially by a key executive, can signal reduced confidence or simple diversification; investors typically interpret sizeable Form 144 activity as a modest negative indicator unless offset by compelling corporate developments.

Item 5.07 鈥� Results of IonQ鈥檚 2025 Annual Meeting of Stockholders

IonQ, Inc. (NYSE: IONQ) reported the voting outcomes from its 17 June 2025 annual meeting. Two Class I directors were successfully re-elected to serve until the 2028 meeting: Niccolo de Masi received 60,572,382 鈥淔or鈥� votes versus 1,986,960 withheld, while Inder M. Singh received 50,750,772 鈥淔or鈥� votes versus 11,808,570 withheld. Each proposal carried 52,916,886 broker non-votes.

The non-binding 鈥渟ay-on-pay鈥� proposal passed with 39,900,600 votes in favor (鈮�64 %), 22,233,654 against (鈮�35 %), and 425,088 abstentions, suggesting a material minority of shareholders question current compensation practices.

Shareholders overwhelmingly ratified Ernst & Young LLP as independent auditor for FY 2025, delivering 114,159,284 鈥淔or鈥� votes (鈮�99 %), 588,969 against, and 727,975 abstentions.

No other matters were presented and the Form 8-K contained no financial performance updates, transactions, or strategic announcements.

IonQ director William F. Scannell received a grant of 5,513 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Scannell now beneficially owns 140,560 shares directly.

Key details of the RSU grant:

• The RSUs were granted at $0 exercise price
• Vesting occurs at the earlier of: - The 2026 Annual Meeting date (or day prior if service ends at meeting) - June 18, 2026
• Vesting is contingent on continued service as Board member

This Form 4 filing represents standard equity compensation for board service, aligning the director's interests with shareholders through equity ownership. The transaction was executed under normal circumstances with no indication of unusual trading patterns.